Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry

被引：0
|
作者：
Kim, Ji-Won [1 ]
Jung, Ju-Yang [1 ]
Suh, Chang-Hee [2 ]
Kim, Hyoun-Ah [1 ]
机构：
[1] Ajou Univ, Sch Med, Suwon, South Korea
[2] Ajou Univ Hosp, Suwon, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0517
引用
收藏
页码：1050 / 1052
页数：3
相关论文
共 50 条
  • [41] Patient Disease Trajectories in Baricitinib 2-mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
    Genovese, Mark
    Weinblatt, Michael
    Wu, Jianmin
    Jia, Bochao
    Quebe, Amanda
    Sun, Luna
    Chen, Yun-Fei
    Helt, Cameron
    Griffing, Kirstin
    Reis, Paulo
    Pope, Janet
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1129 - 1129
  • [42] GASTRO-INTESTINAL PERFORATIONS AMONG RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGIC DMARDS: A NATIONWIDE SWEDISH COHORT STUDY
    Barbulescu, A.
    Askling, J.
    Frisell, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 164 - 165
  • [43] Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab
    Yosuke Masamoto
    Kazuki Taoka
    Hiroaki Maki
    Mineo Kurokawa
    Annals of Hematology, 2022, 101 : 2795 - 2797
  • [44] Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab
    Masamoto, Yosuke
    Taoka, Kazuki
    Maki, Hiroaki
    Kurokawa, Mineo
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2795 - 2797
  • [45] TREATMENT RESPONSE OF INTRAVENOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON THE LEVEL OF PRIOR EXPOSURE TO BIOLOGIC THERAPY: RESULTS FROM THE KOBIO
    Shin, K.
    Lee, S-K.
    Oh, S.
    Kim, H-A.
    Song, Y. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 954 - 954
  • [46] SEVERE INFECTIONS IN RHEUMATOID ARTHRITIS (RA) ARE RELATED TO THE USE OF BIOLOGIC DMARDS. ASSESSMENT OF REAL-LIFE PATIENTS
    Arce-Salinas, C. A.
    Tripp-Aguilar, A.
    Amaya-Estrada, J. L.
    Rodriguez-Garcia, F.
    Espinosa-Ortega, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1375 - 1375
  • [47] Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
    Strangfeld, A.
    Richter, A.
    Siegmund, B.
    Herzer, P.
    Rockwitz, K.
    Demary, W.
    Aringer, M.
    Meissner, Y.
    Zink, A.
    Listing, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03) : 504 - 510
  • [48] THE CORRELATION BETWEEN EROSION AND BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DENOSUMAB AND BIOLOGIC DMARDS: A PROSPECTIVE COHORT STUDY
    Izumi, K.
    Kaneko, Y.
    Hasegawa, T.
    Takeuchi, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 699 - 699
  • [49] Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
    Genovese, Mark
    Weinblatt, Michael
    Wu, Jianmin
    Jia, Bochao
    Quebe, Amanda
    Sun, Luna
    Chen, Yun-Fei
    Helt, Cameron
    Bacani, A. Kirstin
    Reis, Paulo
    Pope, Janet
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [50] Efficacy and safety of baricitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic DMARDs and/or biological DMARDs: Data from a local registry
    Rosas, Jose
    Senabre-Gallego, Jose Miguel
    Santos-Soler, Gregorio
    Bernal, Jose Antonio
    Bas, Ana Pons
    REUMATOLOGIA CLINICA, 2022, 18 (03): : 188 - 189
12345